[1] Vaidyanathan G, Zhao XG, Larsen RH, et al. 3-[211At]-astato-4-fluorobenzylguanidine:a potential therapeutic agent with prolonged retention by neuroblastoma cells[J]. Br J Cancer, 1997, 76(2):226-233.
[2] Cunningham SH, Maris RJ, Wheldon TE, et al. Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissio[J]. Br J Cancer, 1998, 77(12):2016-2018.
[3] Zhuang ZP, Kung MP, Mu MU, et al. 99Tcm-labelled MIBG derivatives:Novel 99Tcm complexes as myocardial imaging agents for sympathetic neurons[J]. Bioconjugate Chem, 1999,10(2):159-168.
[4] Stevens MJ, Raffel DM, Allman KC, et al. Regression and progression of cardiac sympathetic dysinnervation complicating diabetes:an assessment by C-11 hydroxyephedrine and positron emission tomography[J]. Metabolism, 1999, 48(1):92-101.
[5] Merlet P, Pouillart F, Dubois-Rande JD, et al. Sympathetic nerve alterations assessed with 123I-MIBG in the failing human heart[J]. J Nucl Med, 1999, 40:224-231.
[6] Merlet P, Benvenuti C, Moyse D, et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy[J]. J Nucl Med, 1999, 40:917-923.
[7] Maunoury C, Agostini D, Acar P, et al. Impairment of cardiac neuronal function in children dilated cardiomyopathy:an 123I-MIBG scintigraphic Study[J]. J Ncul Med, 2000, 41:400-404.
[8] Bengel FM, Barthel P, Matsunari I, et al. Kinetics of 123I-MIBG after acute myocardial infarction and reperfusion therapy[J]. J Nucl Med, 1999, 40:904-910.
[9] Sakata K, Shirotani M, Yoshida H, et al. Cardiac sympathetic nervous system in early essential hypertension assessed by 123I-MIBG[J]. J Nucl Med, 1999, 40:6-11.
[10] Estorch M, Camprecios M, Flotats A, et al. Sympathetic reinnervation of cardiac allografts evaluated by 123I-MIBG imaging[J]. J Nucl Med, 1999, 40:911-916.
[11] Takatsu H, Nishida H, Matsuo H, et al. Cardiac sympathetic denervation from the early stage of Parkinson's disease:clinical and experimental studies with radiolabelled MIBG[J]. J Nucl Med, 2000, 41(1):71-77.
[12] Druschky A, Hilz MJ, Platsch G, et al. Differentiation of Parkinson's disease and multiple system atrophy in early disease stages by means of I-123-MIBG SPECT[J]. J Neurol Sci, 2000, 175(1):3-12.
[13] Reinhardt MJ, Jungling FD, Krause TM, et al. Scintigraphic differentiation between two forms of primary dysautonomia early after onset of autonomic dysfunction:value of cardiac and pulmonary iodine-123 MIBG uptake[J]. Eur J Nucl Med, 2000, 27(5):595-600.
[14] Owens J, Bolster AA, Prosser JE, et al. No-carrier-added 123I-MIBG:an initial clinical study in patients with phaeochromocytoma[J]. Nucl Med Commun, 2000, 21(5):437-440.
[15] Kuin A, Rutgers M, van der Valk MA, et al. Bioavailability and toxicity after oral administration of m-iodobenzylguanidine (MIBG)[J]. Br J Cancer, 1999, 79(5-6):802-806.
[16] Boyd M, Cunningham SH, Brown MM, et al. Noradrenaline transporter gene transfer for radiation cell kill by 131I metaiodobenzylguanidine[J]. Gene Ther, 1999, 6(6):1147-1152.